The Brosius laboratory focuses on targeting pathways and networks that are critical for the development and progression of diabetic kidney disease with the aim of identifying new targets for treatments that can be quickly developed for patient treatment. We collaborate extensively with others in "team science" projects that utilize systems biology approaches in the pursuit of effective treatments and biomarkers for diabetic kidney disease and other diabetic complications, including vascular disease. We utilize mouse models that are modified to "humanize" both the disease process and the response to treatments to try to accelerate this research.
Link to PubMed Citations
Berthier CC, Zhang H, Schin ML, Henger A, Nelson RG, Yee B, Boucherot A, Carter-Su C, Argetsinger LS, Rastaldi MP, Brosius FC*, Kretzler, M. Enhanced Expression of JAK-STAT Pathway Members in Human Diabetic Nephropathy, Diabetes, 2009, Feb;58(2):469-77. (*corresponding author).
Atkins KB, Irey B, Xiang N, Brosius FC 3rd. A rapid, PPARgamma-dependent, effect of pioglitazone on phosphorylation of myosin phosphatase targeting subunit - MYPT. Am J Physiol Cell Physiol, 2009 Mar 11, 296(5):C1151-61
Brosius FC 3rd, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, Harris RC, Kakoki M, Kretzler M, Leiter EH, Levi M, McIndoe RA, Sharma K, Smithies O, Susztak K, Takahashi N, Takahashi T; Mouse models of diabetic nephropathy J Am Soc Nephrol, 2009 Dec;20(12):2503-12.
Pop-Busui R, Roberts L, Pennathur S, Kretzler M, Brosius FC, Feldman, EL. The Management of diabetic Neuropathy in CKD. Am J Kidney Dis, 2009 Dec 28. [Epub ahead of print]
Zhang H, Schin M, Saha J, Burke K, Holzman LB, Filipiak W, Saunders T, Heilig C, Brosius FC 3rd. Podocyte Specific Overexpression of GLUT1 Surprisingly Reduces Mesangial Matrix Expansion in Diabetic Nephropathy in Mice. Am J Physiol Renal Physiol. 2010 Jul;299(1):F91-8.
Wang Y, Heilig K, Saunders T, Minto A, Deb DK, Chang A, Brosius F, Monteiro C, Heilig CW. Transgenic overexpression of GLUT1 in mouse glomeruli produces renal disease resembling diabetic glomerulosclerosis. Am J Physiol Renal Physiol. 2010 Jul;299(1):F99-F111.
Ju W, Brosius FC 3rd. Understanding kidney disease: toward the integration of regulatory networks across species. Semin Nephrol. Sep 2010;30(5):512-9
Buller C, Heilig CW, Brosius FC 3rd. GLUT1 enhances mTOR activity independently of TSC2 and AMPK, Am J Physiol Renal Physiol. 2011 Sep; 301(3):F588-96.
Komorowski CV, Brosius FC 3rd, Pennathur S, Kretzler M. Perspectives on Systems Biology Applications in Diabetic Kidney Disease. J Cardiovasc Transl Res. 2012 Aug;5(4):491-508. Epub Jun 26.
Hodgin JB. Nair V, Zhang H, Randolph A, Harris RC, Nelson RG, Weil EJ, Patel J, Brosius FC 3rd*, Kretzler M. Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. Diabetes. 2013;62(1):299-308. (*corresponding author)
Brosius FC 3rd, Alpers CW. New Targets for Treatment of Diabetic Nephropathy: What We Have Learned from Animal Models, Current Opinion in Nephrology and Hypertension, 2013;22(1):17-25.
Brosius FC 3rd, Pennathur S. How to Find a Prognostic Biomarker for Progressive Diabetic Nephropathy, Kidney International, 83(6):996-8, 2013.
Guzman J, Jauregui AN, Merscher-Gomez S, Muresan C, Diez-Sampedro A, Szust, J, Yoo T-H, Villarreal R, Molano RD, Pedigo C, Maiguel D, Kahn B, Huber TB, Burke III GW, Abel ED, Brosius FC, Fornoni A. Podocyte specific GLUT4 deficient mice have fewer and larger podocytes and are protected from diabetic nephropathy, Diabetes, 2014 Feb;63(2):701-14.
Brosius FC, Coward RJ. Podocytes, signaling pathways, and vascular factors in diabetic kidney disease, Advances in Chronic Kidney Disease, 2014; 21(3):304-10.